Navigation Links
Zyflamend inhibits 78 percent of prostate cancer cells

An article published in the October issue of the journal Nutrition and Cancer says that Zyflamend, an herbal extract from olive oil could end the search for a drug to beat prostate cancer.//

It was found that this element caused the prostate cancer cells to commit "suicide." The researchers report that the drug had the ability to inhibit 78 percent of the cancer cell growth plus it also caused "apoptosis". This is the natural process by which a cell dies. Cell death in this way is a physiological process and Zyflamend's ability to trigger this action bodes well for the future, according to the lead researcher in the study, Dr. Debra L. Bemis of Columbia University College of Physicians and Surgeons, New York. "Together, these results suggest that Zyflamend might have some chemopreventive utility against prostate cancer in men," she said.

It was also found that Zyflamend had both COX-1 and COX-2 inhibitory effects on the cancer cells and was shown to decrease the activity of both these enzymes in a dramatic manner in the laboratory setting. "We are currently conducting a Phase I clinical trial for men with a pre-cancerous lesion of the prostate -- prostatic intraepithelial neoplasia -- to gain some information as to Zyflamend's potential to prevent or slow... progression to prostate cancer," Dr. Bemis concluded.

The COX inhibitors are known to have some effect on prostate cancer cells, but are contraindicated in heart disease since they have adverse impact on the heart. Zyflamend was seen to have the similar chemical structure as that of Aspirin.

Related medicine news :

1. Garlic inhibits fungal growth and protects food
2. Pharmacia may take 51.5 percent Abbott stake
3. NHS Forced to Borrow Money at Rates of 10 percent
4. Thirty percent of nurses distressed with verbal and physical abuse
5. 17 percent rise in childhood cancer cases due to modern lifestyles
6. Supercentenarian Center to study longevity
7. Better prostate cancer detection
8. Protective effects of tomatoes in prostate cancer
9. Early detection of prostate cancer
10. Fingerprinting prostate cancer
11. No link between blood groups and prostate cancer
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology: